Is The Cost-Effectiveness Threshold Cost-Effective in Cancer Therapy?

• Autorzy: Łukas Kaczyński , Beata Serafin , Patrycja Prząda-Machno , Marcin Kaczor
• Języki publikacji: EN

Abstrakty

EN

To compare availability of innovative cancer drugs in countries with established cost-effectiveness threshold (Great Britain, Czech Republic, Sweden and Poland) and where this criterion is not used (Germany, France, Italy), and to assess the relationship between the reimbursement system and the expenditures and health outcomes. The analysis of reimbursement decisions concerning innovative cancer drugs approved by the European Medicines Agency in the years 2012-2013 and the available data concerning incidence, 5-year relative survival rate and the treatment costs of breast, lung, colon and prostate cancer. The assessment included 19 innovative drugs. Most of them were covered by reimbursement in countries without a cost-effectiveness threshold - 80.7%, compared to the countries with a cost-effectiveness threshold - 59.6% (48.7% including Poland). Three products were financed in all reimbursement systems, with the exception of Poland: Perjeta, Xalkori and Xtandi. In countries without the cost-effectiveness threshold the health outcomes expressed as 5-year relative survival were better compared to EU in general or to most of countries which use the cost-effectiveness threshold, whereas expenditures per capita in most cancers were diversified - large (15-27 €, Germany) or similar to the countries with the cost-effectiveness threshold (6-13 €, France and Italy). In Poland for most evaluated cancers the lowest 5-year relative survival was noted, with the lowest expenditure per capita (5-9 €) simultaneously (original abstract)

Słowa kluczowe

EN

Effectiveness; Medical treatment; Costs; Cancer

PL

Efektywność; Leczenie; Koszty; Choroby nowotworowe

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2015
• Numer: nr 2
• Strony: 68--79

Twórcy

autor

Łukas Kaczyński

• Aestimo s.c., Kraków, Polska

autor

Beata Serafin

• Aestimo s.c., Kraków, Polska

autor

Patrycja Prząda-Machno

• Pfizer Polska, Warszawa, Polska

autor

Marcin Kaczor

• Aestimo s.c., Kraków, Poland ; Uniwersytet Jegielloński Collegium Medicum, Kraków, Poland

Bibliografia

• Bae YHJ., Mullins D. Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs? J. Manag. Care. Pharm. 2014; 20: 1086-1092
• National institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. 2009 [cited 15.10.2015]. Available from: https://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-paper2;
• Aitken M. Impact of cost-per-QALY reimbursement criteria on access to cancer drugs. IMS Institute for healthcare informatics. 2014; [cited 15.10.2015]. Available from: https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/IHII_CPQ_Impact_on_Access_to_Cancer_Drugs.pdf;
• Wojciechowska U., Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii - Instytut im. Marii Skłodowskiej - Curie; [cited 15.10.2015]. Available from: http://onkologia.org.pl/raporty/
• De Angelis R., San M., Coleman MP. et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014; 15:23-34
• GLOBOCAN 2012. Estimated Cancer incidence, mortality and prevalence worldwide in 2012. 2012; [cited 15.10.2015]. Available from: http://globocan.iarc.fr/Default.aspx;
• Luengo-Fernandez R., Leal J., Gray A., Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013; 14:1165-1174
• Rémuzat C., Toumi M., Falissard B. New drug regulations in France: what are the impacts on market access? Part 1 - Overview of new drug regulations in France. Journal of Market Access & Health Policy 2013; 1: 20891
• Pricing and Reimbursement Questions. Conférence Bleue. European Lawyers' Conference on Pharmaceutical and Health Care Affairs. 2015; [cited 15.10.2015]. Available from: http://www.arthurcox.com/wp-content/uploads/2015/06/Pricing-and-Reimbursement-Questions.pdf;
• Bergmann L., Enzmann H., Broich K. et al. Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe? Ann. Oncol. 2014; 25: 303-306
• IMS Consulting Group. AMNOG: Seven Learnings for Strategic Market Access Decisions in Germany. 2012; [cited 15.10.2015]. Available from: http://pl.scribd.com/doc/290575228/AMNOG-Seven-Learnings-Strategic-Access-Germany

Identyfikatory

DOI

10.7365/JHPOR.2015.2.6